New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention

Domenico Di Raimondo* , Giuseppe Miceli* , Gaia Musiari, Antonino Tuttolomondo, Antonio Pinto

Dipartimento Biomedico di Medicina interna e Specialistica, University of PALERMO, Palermo, Italy

Contributions: (I) Conception and design: D Di Raimondo, G Miceli; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to the work.

Correspondence to: Domenico Di Raimondo, MD, PhD. UOC di Medicina Interna con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy. Email: domenico.diraimondo@unipa.it.

Abstract: Exercise training prevents the onset and the development of many chronic diseases, acting as an effective tool both for primary and for secondary prevention. Various mechanisms that may be the effectors of these beneficial effects have been proposed during the past decades: some of these are well recognized, others less. Muscular myokines, released during and after muscular contraction, have been proposed as key mediators of the systemic effects of the exercise. Nevertheless the availability of an impressive amount of evidence regarding the systemic effects of muscle-derived factors, few studies have examined key issues: (I) if skeletal muscle cells themselves are the main source of cytokine during exercise; (II) if the release of myokines into the systemic circulation reach an adequate concentration to provide significant effects in tissues far from skeletal muscle; (III) what may be the role carried out by muscular cytokine regarding the well-known benefits induced by regular exercise, first of all the anti-inflammatory effect of exercise. Furthermore, a greater part of our knowledge regarding myokines derives from the muscle of healthy subjects. This knowledge may not necessarily be transferred per se to subjects with chronic diseases implicating a direct or indirect muscular dysfunction and/or a chronic state of inflammation with persistent immune-inflammatory activation (and therefore increased circulating levels of some cytokines): cachexia, sarcopenia due to multiple factors, disability caused by neurological damage, chronic congestive heart failure (CHF) or coronary artery disease (CAD). A key point of future studies is to ascertain how is modified the muscular release of myokines in different categories of unhealthy subjects, both at baseline and after rehabilitation. The purpose of this review is to discuss the main findings on the role of myokines as putative mediators of the therapeutic benefits obtained through regular exercise in the context of secondary cardiovascular prevention.

Keywords: Myokines; regular exercise; cardiovascular disease (CVD); cerebrovascular disease; cardiac rehabilitation

Submitted May 03, 2017. Accepted for publication Jul 18, 2017.
doi: 10.21037/atm.2017.07.30

View this article at: http://dx.doi.org/10.21037/atm.2017.07.30

Introduction

Regular physical activity protects against several pathologic conditions, the main of which are type 2 diabetes, cardiovascular diseases (CVD), colon cancer, breast cancer, and dementia (1). Recently, it has been proposed that the protective effects of physical activity could also be attributed to the muscular production of various peptide mediators called myokines. Once they are secreted during skeletal muscle contraction, they may carry out autocrine, paracrine and endocrine activities triggering specific metabolic pathways in different tissue and organs far from the muscle
such as visceral fat, bone, liver, and nervous system, among others (1-4).

Since skeletal muscle represents the most extended organ in the human body, the identification of myokines is an important finding and may provide a biochemical explanation in recognizing molecular mechanisms that provide health beneficial effects in chronic disorders associated with systemic low-level inflammation (1,5).

Sedentary life has a higher prevalence than that of all other cardiovascular modifiable risk factors (6,7). In recent times, the profits of regular exercise were extended to subjects with established CVD as a treatment option to improve the natural history of the disease in secondary prevention (8,9). This was a revolutionary changing of view because, for a long time, physical rest had been prescribed for patients with CVD.

Numerous biological effects are considered responsible for the primary and secondary prevention of CVD and for the reduction in the rate of death and inactivity associated with routine exercise. In fact, regular physical activity has been demonstrated to reduce abdominal adiposity and improve weight control (10-12), reduce triglyceride levels, increase high-density lipoprotein (HDL) cholesterol levels and decrease low-density lipoprotein (LDL)-to-HDL ratios (10,13), ameliorate glucose homeostasis and insulin sensitivity (14), lower blood pressure (BP) (15,16), improve autonomic tone (17,18), balance blood coagulation (19,20), augment coronary blood flow (21), improve cardiac function (22,23) and enhance endothelial function (24-26). Moreover, physical activity seems to play a fundamental role in the primary and secondary prevention of CVD modulating chronic inflammation as demonstrated by high circulating levels of inflammatory mediators that have been shown to be directly associated with most of the chronic diseases (1,27).

Regular exercise is also associated with improved psychological wellness through the reduction of stress, anxiety, and depression (10,28,29). Psychological health is recognized to be important for the prevention and management of CVD.

Finally, findings for the improvements of physical activity in the treatment and rehabilitation of subjects with chronic CVD should be based on well-designed randomized controlled trials (RCTs) (30). Up until now, a large number of RCTs studying the therapeutic role of physical activity in specific chronic disease has been accomplished allowing systematic reviews and meta-analyses. The intent of this paper is to analyze, review and discuss the present findings on the role of myokines as putative mediators of the therapeutic benefits obtained in the main CVD: essential hypertension, chronic heart failure (HF), coronary artery disease (CAD) and in the cerebrovascular diseases after regular physical activity or specific rehabilitation programs.

**Myokines expression and secretion by skeletal muscle cells**

Many excellent reviews have tried to summarize the findings that skeletal muscle represents a secretory organ (2,31-34), having the capacity to release hundreds of myokines, and the possible clinical implications of this evidence. Currently myokines are defined as proteins produced by skeletal muscle that are not necessarily induced by exercise nor do they have to have a systemic function but only work with a paracrine or autocrine mechanism (2,35). In order to underline the concept that not all the myokines have the same clinical relevance, some authors support the alternative definition of “exercise factors”, referring to a subgroup of myokines released by skeletal muscle in response to exercise and that is secreted into the circulation working in a “hormone-like” manner (2,36). For the purpose of this review, the list of the myokines potentially involved is much more limited, in fact, the greater part of the myokines identified to date is the result of the secretome analysis over human muscle biopsies collected before and after acute exercise (37) often lacking concrete confirmations of any clinical effect. The main myokines of which we discuss in this review are interleukin (IL)-6, IL-8, IL-15, brain-derived neurotrophic factor (BDNF), monocyte chemotactic protein 1 (MCP1) and myostatin. These are the only molecules which we have enough information in unhealthy subjects in the context of cardiac rehabilitation and secondary cardiovascular prevention.

It should be underlined that any variation of the gene expression of the muscular production and/or of the plasmatic release of the myokines after exercise is generally dependent on the combination of mode, intensity, and duration of exercise (38) and that often is impossible to ascertain that a molecule identified as a myokine is of exclusive production of skeletal muscle (2).

The prototype myokine, IL-6, seems to be mostly responsible for a strong metabolic activity during exercise, by ensuring that enough fuel gets to the contracting muscle during exercise. Several works during last decades have
increased levels of IL-6 serve to sustain muscular and not-
but is reasonable to hypothesize that during acute exercise
training will decrease plasmatic levels of IL-6 (45,47,48),
circulation (46); there is only moderate evidence that regular
comparing IL-6 plasma levels before and after training.

The skeletal muscle is a major contributor to IL-6 in the
obtained in subjects with coronary heart disease (CHD),
sex-matched controls. Conflicting results have been
reported to decrease the expression of skeletal muscle
properties), IL-8 and IL-15.

TNF-receptor (sTNF-R) (with prevalent anti-inflammatory
such as IL-1 receptor antagonist (IL-1 ra), IL-10, soluble
chemokines and adhesion molecules, enhancing endothelial
dysfunction and stimulating coagulation (42,43). In some
studies IL-6 is considered as a sensor in the muscle, being
released when the local glycogen concentration is low.
It is plausible that a large number of IL-6, derived from
muscle, reaching the circulation, may act as a hormone
determining mobilization of extracellular substrates and/or
to increased substrate delivery during exercise (44). During
acute physical activity, in addition to high circulating
concentration of IL-6, other myokines are often detectable
such as IL-1 receptor antagonist (IL-1 ra), IL-10, soluble
TNF-receptor (sTNF-R) (with prevalent anti-inflammatory
properties), IL-8 and IL-15.

A very limited number of papers tried to ascertain
the effect of regular exercise training on IL-6 levels. In
patients with chronic HF, regular exercise training is
reported to decrease the expression of skeletal muscle
IL-6 mRNA (45), although the basal IL-6 levels of this
category of patients are higher than healthy age- and
sex-matched controls. Conflicting results have been
obtained in subjects with coronary heart disease (CHD),
comparing IL-6 plasma levels before and after training.
The skeletal muscle is a major contributor to IL-6 in the
circulation (46); there is only moderate evidence that regular
training will decrease plasmatic levels of IL-6 (45,47,48),
but is reasonable to hypothesize that during acute exercise
increased levels of IL-6 serve to sustain muscular and not-
muscular metabolism (IL-6 also augments hepatic glucose
and increases adipose tissue fatty acid release) whereas after
regular exercise the genomic adaptation to training makes
less necessary the role of IL-6, whose circulating levels are
in fact reduced, and in order to avoid the disadvantageous
effects of a chronic elevation of IL-6, is moreover promoted
the clearance of this cytokine through the hepatosplanchnic
blood flow.

IL-15 is a myokine synthesized in human skeletal muscle, and
has been shown to have an anabolic effect on muscle growth,
and also to play a role in lipid metabolism (49). Recently, it
was demonstrated that IL-15 mRNA concentration was
upregulated in human skeletal muscle following physical
activity (50), suggesting that IL-15 could reach high levels
within the muscle after regular exercise. Furthermore, there
is a negative association between plasma IL-15 levels and fat
mass (51).

BDNF is a neurotrophin involved in regulating
growth and survival of existing neurons (52), and also
growth and differentiation of new neurons and synapses,
playing an active role in learning and memory (53-57).
Various lines of evidence reported low levels of circulating
BDNF in individuals affected by both obesity and type 2
diabetes (58) as well as in several chronic neurological
diseases (Alzheimer's disease, major depression, impaired
cognitive function). BDNF mRNA and protein synthesis
were upregulated in human skeletal muscle after physical
activity or after electrical stimulation; unfortunately, to date,
no study has been able to find muscle-derived BDNF into
the circulation. BDNF appears to be a myokine working
only with autocrine or paracrine action determining
powerful effects on peripheral metabolism [for example, fat
oxidation with a consequent effect on the amount of adipose
tissue (59)].

MCP1 is a chemokine released into the bloodstream
from skeletal muscle after specific types of exercise such as
marathon running or high-duration resistance exercise (60).
The systemic role in the release of this pro-inflammatory
mediator after acute high-intensity endurance training is
debated, being possibly merely linked to an acute skeletal
muscle injury (61). After chronic training the behavior of
plasmatic MCP1 is similar to IL-6, IL-8 and other pro-
flammatory and pro-atherosclerotic mediators: decrease. This
finding has been reported in various categories of unhealthy
subjects such as patients with metabolic syndrome (62), subjects with chronic HF (63), persons with
CAD (64).
Myostatin is a molecule of great interest expressed by skeletal muscle because of its potential therapeutic role. It is a released ligand of growth and differentiation factors belonging to the transforming growth factor (TGF) superfamily. Several lines of research suggest that myostatin may be involved in the regulation of muscle mass (65,66) through its autocrine and paracrine effects once it has reached an appropriate concentration into the circulation (67). Myostatin has been shown to have a role also in the crosstalk between skeletal muscle and adipose tissue and may exert an effect on insulin sensitivity (68), although it has been recognized to have not a direct effect on adipocytes function and metabolism. However, an enhanced concentration of myostatin in muscle mass provokes to a higher energy amount, increased lipid uptake, and more active metabolism, reducing the volume of adipose tissue (69). Myostatin, acting as a key regulator of skeletal muscle mass, is elevated in advanced stages of chronic HF, possibly acting as a mediator of cardiac cachexia. Lenk et al. reported that 12 weeks of exercise training may induce a significant reduction of myostatin in skeletal muscle, demonstrating the reversibility of the muscle wasting in chronic HF (70). Higher levels of myostatin than controls have been found also in patients with chronic diseases associated with decreased mobility, inflammation, and weight loss such as chronic obstructive pulmonary disease (COPD) (71,72) or end-stage chronic kidney disease (CKD) undergoing to hemodialysis (73).

The list of myokines is steadily increasing over the years; several of which potentially of interest. Fibroblast growth factor (FGF)-21, is a member of the FGF family involved in carbohydrate and lipid homeostasis that seems to be associated with obesity, diabetes and atherosclerotic damage (74,75).

Apelin, is an interesting insulin-related factor localized in cardiomyocytes and vascular cells that seem to play a key role in the regulation of vascular tone and cardiovascular function (76,77).

Follistatin like-1 (FSTL1) is a glycoprotein that has been associated with an improved vascular health and function, counteracting endothelial dysfunction (78).

The finding that skeletal muscle during contraction expresses and releases many myokines in the circulation suggests a relationship between myokines and metabolism both in physiologic and in pathologic conditions. Since circulating markers of inflammation are chronically elevated in CVD and other vascular diseases, a change in their levels induced through physical activity may play a role in the treatment of these diseases; in the second part of this review, we tried to discuss this issue, referring to the main vascular pathologic conditions.

**Arterial hypertension**

The main guidelines indicate that routine exercise is considered to play a fundamental role in the prevention and treatment of hypertension (79). Several studies demonstrated that exercise is associated with a lower BP, and meta-analyses of RCTs have indicated that chronic dynamic aerobic endurance training can be effective to reduce BP levels both in normotensives and in hypertensive subjects (16,80-83). A recent meta-analysis (84) examines the effect of regular dynamic aerobic endurance exercise on resting and ambulatory BP, on BP-regulating mechanisms, and on concomitant cardiovascular risk factors, like body fatness, waist circumference, blood lipids, and glucose/insulin dynamics, finding beneficial effects of exercise in all outcomes and concomitant risk factors. They recognized that the BP decline was most evident in the hypertensive study groups, but a good BP reduction may also be found in normotensives and pre-hypertensive subjects (85). A reduction in the activity of the autonomic nervous system is supposed to be involved in the decrease of BP after exercise, as demonstrated by the 29% lower plasma norepinephrine levels in trained subjects when compared with unfit counterparts. Interestingly, some studies recognized a lack of an effect on BP during sleep (86), when sympathetic activity is reduced, that may be compatible with the hypotensive effect of the sympathetic nervous system after regular exercise. The 20% decrease of plasma renin activity suggests the role of the renin-angiotensin system (87,88). Moreover, the decreased level of plasma renin activity supports the hypothesis that the reduction in the activity of the sympathetic nervous system also affects the kidney, which is the most potent factor involved in long-term BP regulation (89). Another import role in the exercise-induced reduction of BP levels is played also by the consequent reduction of insulin resistance and improvement of the endothelial function obtained through regular training (1).

Other studies conducted with untreated patients with mild essential hypertension who walked quickly for 30 minutes 5 to 7 times per week for 12 weeks found a reduction in systolic and diastolic BPs and an augmented forearm blood flow in response to acetylcholine infusion.
This increased blood flow seems blocked by a nitric oxide (NO) inhibitor (90), suggesting a role for NO. Sedentary hypertensive rats seem to have augmented adrenergic agent-induced vasoconstricting responses, associated with reduced NO expression, of thoracic aortas and carotid arteries compared with exercise-trained hypertensive rats (91). Moreover, plasma nitrate (an index of NO quantity) was decreased in sedentary hypertensive rats compared with allowed access to 35 days of voluntary wheel running (92). Interestingly, this effect persists for 36 h, but exercised rats returned to sedentary levels by the 7th day of detraining.

The most validated mechanism supposed to lower BP through physical activity contemplates the synergism of both vascular and neurohumoral systems that determine a reduction in total peripheral resistance and catecholamines level (93). A comprehensive study of the benefits that exercise exerts on BP is very complicated since physical activity is involved in many other different effects like lipid and glucose control, weight loss, improved endothelial function and enhanced antioxidant capacity. Some data suggest that a genetic link is present between the grade of BP reduction and acute and chronic exercise in accord to the variability of results in individuals that was encountered (94). Moreover, angiotensin-converting enzyme (ACE), apolipoprotein E (apoE), and lipoprotein lipase (LPL) genotypes can be found in hypertensive subjects whose BP and cardiovascular risk can be markedly reduced with regular exercise. These genotype-dependent responses can support the hypothesis that endurance physical activity can lead to a more significant improvement of BP and circulating lipid levels in genetically advantaged subjects. Despite this significant amount of evidence supporting the role of regular exercise in improving the BP profile both in normotensive and in hypertensive subjects, to date no studies addressed the issue of the possible role carried out by myokines in causing these beneficial effects. Future studies are needed to clarify this topic.

### Cerebrovascular disease

Neuroinflammation represents a key mechanism during both the acute phase of an ischemic stroke and in the recovery phase during the post-stroke rehabilitation. The level of systemic inflammation in stroke patients strongly depends on the diagnostic subtype of stroke and is directly related to the extent of the neurological damage during the acute phase and to the residual disability (95-101). Following neurological rehabilitation, usually initiated early as possible after the clinical stabilization, various authors demonstrated the change of plasma concentrations of different circulating mediators, whose role is under investigation. An increase of the plasmat levels of the most famous neurotrophic factor, BDNF, has been demonstrated after acute aerobic exercise in an intensity-dependent manner both in healthy subjects (102,103) and in multiple sclerosis patients (104). The main origin of exercise-induced circulating BDNF is likely to be the brain rather than the muscle (specific areas of the human brain such as the hippocampus and cerebral cortex) (103,105). Nevertheless with the uncertainty regarding the main source, exercise-induced BDNF may be reasonably considered as an effective mediator of improved neurological health.

Another recently discovered factor associated with exercise-induced neuronal recovery after ischemic injury is the insulin growth factor (IGF)-1. Various reports indicate that IGF-1, released by various tissues including the skeletal muscle, may have a relevant role in neuroplasticity together with BDNF (106-108). IGF-1 would play an active role in mediating the recovery of neuronal function through the rehabilitation, despite an excessive release of IGF-1 is reported to have opposite effects, inducing an increased level of neuroinflammation and a worst outcome (109).

Other putative myokines having a certain neurotrophic activity are various molecules belonging to the family of the neurotrophins (110), the vascular endothelial growth factor (VEGF) (111), the neurotrophin ciliary neurotrophic factor (CNTF) (112), FGF21 (113), even if any significant muscular release of these substances after acute exercise or exercise training is far from being proven.

### Congestive HF

Physical inactivity seems to play a role in the development of a great percentage of cases of congestive heart failure (CHF) and also aggravate conditions associated with previously diagnosed CHF patients. A sedentary lifestyle can account for 9.2% of all cases of CHF. Physical activity of individuals affected by moderate to severe CHF can reduce all-cause mortality by 63% and decreased hospital readmission for HF by 71% (114). Moreover, subjects with CHF improved their quality of life from participating in physical training programs (115). According to 14 RCTs, physical activity showed a physiological favorable effect in CHF patients focusing on short-term training program benefits (116). In the Cochrane systematic...
review of exercise-based interventions for HF (117), the authors concluded that physical activity clearly ameliorates short-term exercise capacity. The meta-analysis by the ExTraMATCH Collaborative Group (118) found that there was no evidence that supervised exercise training programs for CHF patients were dangerous and indeed authors encountered an overall reduction in mortality.

Even if the principal affected organ in CHF is recognized to be the heart, skeletal muscle is thought to be a secondary defective organ involved in reducing exercise tolerance. Moreover, skeletal muscle dysfunction in CHF experiments great benefits with regular physical training, even if the function of the heart remains unaffected by exercise. In many HF subjects, the limitation in skeletal muscle function is more predominant than the hemodynamic impairment due to the cardiac dysfunction (119). In these patients the reduction of the functional capacity may lead to a progressive reduction of the mobility; this condition has shown to increase the risk of appearance of other chronic diseases. The worsening of the health status due to the multiple comorbidities causes further exercise restriction and increased hospitalization and mortality in individuals with symptomatic HF (119). It is recognized that the reductions in physical capacity in CHF are not just secondary to alterations in myocardial function (120). In fact, some indexes of cardiac function like ejection fraction are not improved by exercise in CHF patients (121). On the other hand, exercise capacity does correlate greatly with measures of peripheral muscular strength and endurance which explain the exercise intolerance in CHF patients with cellular alterations in the periphery (122). An interesting study (123) showed that 4–6 months of aerobic training in CHF subjects ameliorate exercise capacity and increase blood flow to the peripheral musculature. These muscular changes are accompanied by a decreased skeletal muscle expression of tumor necrosis factor -alpha, IL-1-beta, and IL-6 (45), with the following reduction of systemic inflammation in these patients.

The precise mechanisms through which regular physical activity determines its positive effect in patients with HF remains not completely clear. Certainly, the significant clinical improvement obtained through the regular training in CHF patients is the result of a complex interplay of different effects:

(I) Improved cardiopulmonary efficiency and pulmonary functional capacity (124);

(II) Amelioration of myocardial perfusion in ischemic subjects by reducing endothelial dysfunction and by inducing new vessel formation by way of intermittent ischemia (118);

(III) Improved myocardial contractility and diastolic filling (125);

(IV) Counteract the muscle wasting and cachexia. Myostatin may be involved in the pathophysiology of cardiac progressive dysfunction in chronic HF. In the already cited study of Lenk et al. (70), chronic HF subjects at baseline showed a two-fold increase of myostatin mRNA (P=0.05) and a 1.7-fold (P=0.01) augmentation of protein content in skeletal muscle compared to healthy subjects. Also in animal models, myostatin seems to be involved: myocardial gene and protein expression are increased in response to chronic volume overload-induced by aortocaval shunt in rats (126) and after acute myocardial infarction in rat cardiomyocytes (127);

(V) Reduction of the systemic inflammation;

(VI) Attenuation of the sympathoexcitation, a typical feature of CHF, helping to restore autonomic balance to the heart even in the persistence of cardiac dysfunction (128);

(VII) Modulation of the cardiac angiotensin receptor, with a secondary restoration of the overactivated renin-angiotensin-aldosterone system (129).

CAD

Many interesting papers have suggested a positive effect of physical activity on coronary vasodilation and endothelial function. Animal studies have largely demonstrated that physical activity determines a flow-mediated epicardial coronary vasodilation that seems to be dependent upon the integrity of the endothelium (130,131).

As we have already discussed, hypertension seems to be associated with decreased expression and/or augmented degradation of vascular NO (132), causing a reduction in vessel vasodilation. The altered availability of vascular NO, expression of endothelial dysfunction, is also involved in the progress of atherosclerosis. Physical activity increases NO expression in endothelial cells (21,133). Vasodilation secondary to exercise training is supposed to be mediated by shear stress (134). In fact, when in studies where fluid flow was increased in culture, endothelial cells register an augmentation of NOS mRNA (135). The augmented levels of NO stimulate vasodilation, which then lessens the enhancing in shear stress across an endothelial cell.
Numerous systematic reviews have shown the fundamental role played by regular training to attenuate or reverse the disease process in patients with CAD. For instance, a systematic review and meta-analysis involving 48 clinical trials (136) indicated that, compared with usual care, cardiac rehabilitation determine a marked reduction of incidence of premature death from any cause and from CVD in particular. In another systematic review, RCTs show that physical activity in documented CHD decrease all-cause mortality by 27% and total cardiac mortality by 31%, but not the rate of non-fatal myocardial infarction (9).

Milani et al. conducted the first studies elucidating the benefits of physical activity and cardiovascular rehabilitation on the plasma levels of C-reactive protein (CRP). They encountered a great reduction in CRP after the 3-month intervention in CAD patients with and without metabolic syndrome (137), in weight gainers and losers (138), and in subjects with or without statin therapy (138). These findings were confirmed by other studies (139-141). An important study (142), assessing the results of aerobic exercise training on concentrations of pro- and anti-inflammatory cytokines, IL-1, IL-6, IL-10, INF-gamma, and CRP in CAD subjects attending a cardiac rehabilitation program demonstrated a consistent reduction of CRP levels after 12 weeks of training, along with a significant decrease of all pro-inflammatory cytokines, IL-1, IL-6, IL-10, INF-gamma, and CRP in CAD subjects attending a cardiac rehabilitation intervention in CAD patients with and without metabolic syndrome (137), in weight gainers and losers (138), and in subjects with or without statin therapy (138). These findings were confirmed by other studies (139-141). An important study (142), assessing the results of aerobic exercise training on concentrations of pro- and anti-inflammatory cytokines, IL-1, IL-6, IL-10, INF-gamma, and CRP in CAD subjects attending a cardiac rehabilitation program demonstrated a consistent reduction of CRP levels after 12 weeks of training, along with a significant decrease of all pro-inflammatory cytokines, IL-1, IL-6, IL-10, INF-gamma, and a great increase in the main anti-inflammatory cytokine: IL-10 (142). In another study (140) after 24 months of exercise, CRP concentration was reduced by 41% and IL-6 levels by 18 % but no change was observed in the percutaneous intervention group. Furthermore, these findings indicate that cardiac rehabilitation and physical activity exert an anti-inflammatory effect independent of statin therapy and weight loss. Similarly, in patients with CAD, 6 months of routine exercise showed an important decrease of IL-6 and other pro-inflammatory cytokines (143). Conversely, Astengo et al. in 62 individuals with stable angina followed for 8 months before and after the intervention of percutaneous coronary intervention (PCI) with a training program that consisted of home-based training on a bicycle ergometer did not find any modifications of plasmatic concentration of pro-inflammatory or anti-inflammatory cytokines (IL-6, IL-8, and IL-10) (144). Niessner et al. (64) evaluated the benefits of endurance exercise on atherosclerosis inflammatory markers in patients with CAD and cardiovascular risk factors. In this study, after a training intervention period of 12 weeks, authors encountered a great reduction of the chemokines IL-8, monocyte chemoattractant protein-1 and of matrix metalloproteinase-9 (MMP-9), that markedly reduced after training, but an insignificant modification of IL-6 and hsCRP (64). These results also indirectly confirm the improved stabilization of the atherosclerotic plaque induced by regular exercise and provide an explanation for the reduced rate of vascular event exercise-related.

In a study examining 86 cardiac surgery patients after 15 days of cardiovascular rehabilitation authors encountered a significant reduction of baseline concentration of IL-8 (145), moreover 15 weeks of exercise training decreased IL-8 plasmatic levels in 27 obese subjects (146) and 12 weeks of controlled endurance exercise lowered IL-8 concentration in individuals with CAD and multiple cardiovascular risk factors (64).

The overall effect observed after cardiac rehabilitation in CHD patients seems to be a reduction of the main circulating cytokines associated with chronic inflammation. In relation to the other main myokines discussed in this review, a higher serum level of myostatin has been related to lower muscle function, given the fact that myostatin acts as a negative regulator of muscular growth. In experimental models of myocardial ischemia-related injury, it has been reported an immediate upregulation of cardiac myostatin (147). This finding allows us to hypothesize both an active role of this molecule in the ischemia-induced myocardial damage and a putative role for the inhibitors of myostatin (i.e., follistatin) induced by exercise in mediating the recovery after an acute episode of CHD.

**Conclusive remarks**

Everyone agreed on having to advise routine exercise among individuals with CVD; several lines of research confirm the significant benefits associated with an improved physical fitness without causing adverse effects on disease progression. Work on subjects with CAD as well as studies on individuals with CHF show that physical activity is associated with lower all-cause mortality compared with controls. Among old patients with CVD, both enhanced fitness levels and a decrease in disease-related symptoms are very important effects although several RCTs are too short to document differences in the true disease progression between groups. Although recommended characteristics of a training program ameliorating aerobic fitness are known to include at least 20 minutes of moderate-intensity training.
twice a week or more during at least 6 weeks in accord to American College of Sports Medicine, in older patients with CVD there is a need of more tailored programs with a specific intensity of exercise. Low-intensity regimens are effective as high-intensity programs in different pathologic conditions such as type 2 diabetes (14) and 5 to 10 minutes of running/day also at slow speed (<6 miles/hour) has been associated with markedly reduced risk of death from all causes and CVD (148), while 92 minutes per week or 15 minutes a day of moderate intensity endurance training have been reported to provide a 14% reduced risk of all-cause mortality and 3 years longer life expectancy (149).

But, on the other hand, several lines of evidence indicate that seems to be a threshold to the dose/effectiveness curve of exercise benefit: to stay on the safe side, the progression of exercise programs must be slow and tailored considering patients’ ability and occurrence of different symptoms. Most of the patients seem to have a positive effect from low- to moderate-intensity exercise training. However, according to the available RCTs, final comprehensive conclusions about the kind of training or dose-response of exercise therapy in the treatment of CVD cannot be finally assessed.

The mechanisms through which regular exercise is of benefit for these categories of subjects are only partly understood. Improved overall control of the main cardiovascular risk factors, enhanced NO-mediated vasodilation and optimized shear stress are surely main benefits. Myokines exert various endocrine effects on various tissues and organs, including adipose tissue, the liver, the pancreas and the brain; mainly exerting a certain metabolic role. Acute exercise and regular training exert very different effects on muscular myokinome, with acute exercise eliciting a more stress-like response compared with a chronic adaptive response observed after habitual exercise. To date, conclusive evidence is lacking regarding a possible role exerted by myokines released into the bloodstream after exercise and acting in a hormone-like manner as mediators of the beneficial effects of exercise in patients in secondary prevention after a vascular event. Other well-known hemodynamic, immunomodulatory and anti-atherosclerotic effects of regular exercise are convincingly able to explain the epidemiologic data showed in this review. But nevertheless, molecules such as myostatin, FGF21 (150,151), apelin, and FSTL1 (152), to name just a few, are promising therapeutic agent of absolute interest. We are expecting ad hoc trials clarifying their real potential.

Regarding the putative anti-inflammatory effect of exercise, confirmed by several lines of evidence, a conclusive message may be similar: the expression of myokines from skeletal muscle is directly related to training intensity, while the anti-inflammatory effect of exercise is not. It is largely accepted that the expression of IL-6 after acute physical activity do not reach consistent concentrations with short durations or low-to-moderate intensity of training (153) and that routine physical activity determines a decrease of IL-6 levels (instead of IL-10 concentration that is shown to increase). On the other hand, many studies reported data that assess how also low-intensity programs of exercise, such as fast walking (16,27,154,155), could produce a consistent decrease in plasma markers of systemic inflammation although does not determine any enhance in circulating cytokines expression (156). These data allow us to hypothesize that other well-known mechanisms (direct and indirect modulation of the activity of immune cells, neuroendocrine changes induced by exercise, reduced fat mass, for example) could explain a great part of the anti-inflammatory effect of exercise. Moreover, in clinical practice, physical activity is not prescribed alone but rather with other lifestyle advice such as weight loss, low-fat diet, smoking cessation or also in combination with pharmacological treatments. How may coexisting treatments influence skeletal muscle myokines expression? Is there any synergic effect between drugs and exercise? Well-designed cross-sectional and longitudinal studies are needed to better explain the potentiality of exercise in the context of cardiac rehabilitation.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

30. Kujala UM. Evidence for exercise therapy in the treatment of chronic disease based on at least three randomized


137. Milani RV, Lavie CJ. Prevalence and profile of metabolic


